Catalyst Pharmaceuticals (CPRX) Depreciation & Amortization (CF) (2010 - 2026)
Catalyst Pharmaceuticals (CPRX) posted Depreciation & Amortization (CF) of $70000.0 for Q1 2026, down 2.78% on a QoQ basis from $72000.0 in Q4 2025, and down 39.13% year-over-year from $115000.0 in Q1 2025.
Catalyst Pharmaceuticals (CPRX) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $70000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 39.13% year-over-year to $70000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $330000.0 (down 22.54% YoY) and the FY2025 annual result came in at $375000.0, down 5.54% from the prior year.
- Depreciation & Amortization (CF) was $70000.0 for Q1 2026 at Catalyst Pharmaceuticals, down from $72000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $116000.0 in Q2 2025 and bottomed at $34000.0 in Q1 2022.
- A 5-year average of $76411.8 and a median of $81000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) sank 64.95% — and 2023, when it jumped 140.0%.
- Catalyst Pharmaceuticals' Depreciation & Amortization (CF) stood at $35000.0 in 2022, then soared by 140.0% to $84000.0 in 2023, then soared by 35.71% to $114000.0 in 2024, then tumbled by 36.84% to $72000.0 in 2025, then fell by 2.78% to $70000.0 in 2026.
- Business Quant data shows CPRX's Depreciation & Amortization (CF) at $70000.0 in Q1 2026, $72000.0 in Q4 2025, and $72000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 70,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70,000.00 |
| Mar 31, 2026 | 70,000.00 |
| Dec 31, 2025 | 72,000.00 |
| Dec 31, 2025 | 72,000.00 |
| Sep 30, 2025 | 72,000.00 |
| Sep 30, 2025 | 72,000.00 |
| Jun 30, 2025 | 116,000.00 |
| Jun 30, 2025 | 116,000.00 |
| Mar 31, 2025 | 115,000.00 |
| Mar 31, 2025 | 115,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Jun 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 91,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Dec 31, 2023 | 84,000.00 |
| Dec 31, 2023 | 84,000.00 |